Movatterモバイル変換


[0]ホーム

URL:


US20110105961A1 - Methods, compositions and apparatuses for facilitating regeneration - Google Patents

Methods, compositions and apparatuses for facilitating regeneration
Download PDF

Info

Publication number
US20110105961A1
US20110105961A1US12/994,421US99442109AUS2011105961A1US 20110105961 A1US20110105961 A1US 20110105961A1US 99442109 AUS99442109 AUS 99442109AUS 2011105961 A1US2011105961 A1US 2011105961A1
Authority
US
United States
Prior art keywords
cells
functional
functionality
cell
degree
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/994,421
Inventor
Lewis S. Gruber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siwa Corp
Original Assignee
Siwa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siwa CorpfiledCriticalSiwa Corp
Priority to US12/994,421priorityCriticalpatent/US20110105961A1/en
Assigned to SIWA CORPORATIONreassignmentSIWA CORPORATIONASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: GRUBER, LEWIS
Publication of US20110105961A1publicationCriticalpatent/US20110105961A1/en
Abandonedlegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

Apparatuses, compositions and methods for removing cells which interfere with regenerative processes. The apparatuses, compositions and methods selectively kill partially functional and/or non-functional cells versus functional cells while protecting functional proliferative cells to the extent that, upon removal of the killed cells by disintegration or scavenging, functional cells replace the partially- or non-functional cells.

Description

Claims (9)

US12/994,4212008-05-232009-05-22Methods, compositions and apparatuses for facilitating regenerationAbandonedUS20110105961A1 (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
US12/994,421US20110105961A1 (en)2008-05-232009-05-22Methods, compositions and apparatuses for facilitating regeneration

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US5584608P2008-05-232008-05-23
US12/994,421US20110105961A1 (en)2008-05-232009-05-22Methods, compositions and apparatuses for facilitating regeneration
PCT/US2009/044951WO2009143411A2 (en)2008-05-232009-05-22Methods, compositions and apparatus for facilitating regeneration

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
PCT/US2009/044951A-371-Of-InternationalWO2009143411A2 (en)2008-05-232009-05-22Methods, compositions and apparatus for facilitating regeneration

Related Child Applications (2)

Application NumberTitlePriority DateFiling Date
US13/332,976ContinuationUS9161810B2 (en)2008-05-232011-12-21Methods, compositions and apparatuses for facilitating regeneration
US14/932,200ContinuationUS20180111982A2 (en)2008-05-232015-11-04Methods, compositions and apparatuses for facilitating regeneration

Publications (1)

Publication NumberPublication Date
US20110105961A1true US20110105961A1 (en)2011-05-05

Family

ID=41340916

Family Applications (4)

Application NumberTitlePriority DateFiling Date
US12/994,421AbandonedUS20110105961A1 (en)2008-05-232009-05-22Methods, compositions and apparatuses for facilitating regeneration
US13/332,976Active2031-08-17US9161810B2 (en)2008-05-232011-12-21Methods, compositions and apparatuses for facilitating regeneration
US14/932,200AbandonedUS20180111982A2 (en)2008-05-232015-11-04Methods, compositions and apparatuses for facilitating regeneration
US15/720,912ActiveUS11261241B2 (en)2008-05-232017-09-29Methods, compositions and apparatuses for facilitating regeneration

Family Applications After (3)

Application NumberTitlePriority DateFiling Date
US13/332,976Active2031-08-17US9161810B2 (en)2008-05-232011-12-21Methods, compositions and apparatuses for facilitating regeneration
US14/932,200AbandonedUS20180111982A2 (en)2008-05-232015-11-04Methods, compositions and apparatuses for facilitating regeneration
US15/720,912ActiveUS11261241B2 (en)2008-05-232017-09-29Methods, compositions and apparatuses for facilitating regeneration

Country Status (18)

CountryLink
US (4)US20110105961A1 (en)
EP (3)EP3170888A1 (en)
JP (6)JP2011521009A (en)
KR (4)KR101537460B1 (en)
CN (2)CN102037119B (en)
AU (1)AU2009248945B2 (en)
BR (1)BRPI0913047A2 (en)
CA (1)CA2724886C (en)
DK (1)DK2789684T3 (en)
ES (2)ES2499395T3 (en)
HU (1)HUE031902T2 (en)
IL (3)IL209513A (en)
MX (2)MX342994B (en)
PL (1)PL2789684T3 (en)
PT (1)PT2789684T (en)
RU (2)RU2640249C2 (en)
WO (1)WO2009143411A2 (en)
ZA (1)ZA201008209B (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US8721571B2 (en)2010-11-222014-05-13Siwa CorporationSelective removal of cells having accumulated agents
US9161810B2 (en)2008-05-232015-10-20Siwa CorporationMethods, compositions and apparatuses for facilitating regeneration
US9649376B2 (en)2010-09-272017-05-16Siwa CorporationSelective removal of age-modified cells for treatment of atherosclerosis
US9993535B2 (en)2014-12-182018-06-12Siwa CorporationMethod and composition for treating sarcopenia
US10358502B2 (en)2014-12-182019-07-23Siwa CorporationProduct and method for treating sarcopenia
US10584180B2 (en)2014-09-192020-03-10Siwa CorporationAnti-AGE antibodies for treating inflammation and auto-immune disorders
US10858449B1 (en)2017-01-062020-12-08Siwa CorporationMethods and compositions for treating osteoarthritis
US10919957B2 (en)2017-04-132021-02-16Siwa CorporationHumanized monoclonal advanced glycation end-product antibody
US10925937B1 (en)2017-01-062021-02-23Siwa CorporationVaccines for use in treating juvenile disorders associated with inflammation
US10961321B1 (en)2017-01-062021-03-30Siwa CorporationMethods and compositions for treating pain associated with inflammation
US10995151B1 (en)2017-01-062021-05-04Siwa CorporationMethods and compositions for treating disease-related cachexia
US11213585B2 (en)2016-06-232022-01-04Siwa CorporationVaccines for use in treating various diseases and disorders
US11518801B1 (en)2017-12-222022-12-06Siwa CorporationMethods and compositions for treating diabetes and diabetic complications
US11833202B2 (en)2016-02-192023-12-05Siwa CorporationMethod and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE)
US11958900B2 (en)2016-04-152024-04-16Siwa CorporationAnti-age antibodies for treating neurodegenerative disorders

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20140189897A1 (en)2011-06-212014-07-03Mayo Foundation For Medical Education And ResearchTransgenic animals capable of being induced to delete senescent cells
CA2859385A1 (en)2011-12-132013-06-20Buck Institute For Research On AgingMethods for improving medical therapies
WO2013158664A2 (en)2012-04-172013-10-24Kythera Biopharmaceuticals, Inc.Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en)2012-08-232018-02-27Buck Institute For Research On AgingTransgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en)2012-08-232018-02-27Buck Institute For Research On AgingTransgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US10279018B2 (en)2012-12-032019-05-07Unity Biotechnology, Inc.Immunogenic compositions for inducing an immune response for elimination of senescent cells
KR20160002848A (en)2013-03-242016-01-08오이신 바이오테크놀로지스Systems and methods for the targeted production of a therapeutic protein within a target cell
US20190269675A1 (en)2014-01-282019-09-05Buck Institute for Research and AgingTreatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US20170216286A1 (en)2014-01-282017-08-03Mayo Foundation For Medical Education And ResearchKilling senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
EP3669881B1 (en)2014-01-282022-03-30Buck Institute for Research on AgingCompositions for use in the treatment of senescence-assiocated eye disease and disorders
US10328058B2 (en)2014-01-282019-06-25Mayo Foundation For Medical Education And ResearchTreating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
WO2017065837A1 (en)2015-10-132017-04-20Siwa CorporationAnti-age antibodies and methods of use thereof
US10889634B2 (en)2015-10-132021-01-12Siwa CorporationAnti-age antibodies and methods of use thereof
CN110678208B (en)2017-01-092024-04-05奥依信生物技术公司 Membrane fusogenic lipid nanoparticles and methods of manufacture and use for producing therapeutic proteins and for treatment
KR20240006702A (en)2017-05-042024-01-15시와 코퍼레이션Diagnostic advanced glycation end-product antibodies
EP3784252A4 (en)2018-04-182022-03-16Oisin Biotechnologies, Inc. FUSOGENIC LIPID DNANOPARTICLES AND METHODS FOR THEIR PRODUCTION AND USE IN TARGET CELL SPECIFIC MANUFACTURE OF A THERAPEUTIC PROTEIN AND TREATMENT OF A TARGET CELL RELATED DISEASE, CONDITION OR DISORDER
EP3826670A1 (en)2018-07-232021-06-02Siwa CorporationMethods and compositions for treating chronic effects of radiation and chemical exposure
WO2020041625A1 (en)2018-08-232020-02-27Siwa CorporationAnti carboxymethyl lysine antibodies and ultrasound for removing age-modified cells
KR20210101481A (en)*2020-02-102021-08-19한국과학기술연구원A device for removing senescent cells comprising an ultrasound output unit
EP4143238A1 (en)2020-05-012023-03-08Siwa CorporationMethods of treating infections
WO2022093195A1 (en)2020-10-272022-05-05Siwa CorporationMethods and compositions for treating osteoarthritis using anti-age antibodies or age antigens
WO2022125776A2 (en)2020-12-092022-06-16Siwa CorporationMethods and compositions for treating kidney diseases
WO2022178218A1 (en)2021-02-192022-08-25Mevion Medical Systems, Inc.Gantry for a particle therapy system
KR102650316B1 (en)*2021-06-182024-03-25재단법인대구경북과학기술원magnetic patch capable of ultrasonic stimulation and its manufacturing method
WO2023023654A1 (en)2021-08-202023-02-23Siwa CorporationMethods and compositions for treating fibrotic diseases
WO2024102157A1 (en)2022-11-092024-05-16Siwa CorporationMethods and compositions for treating diabetes and diabetic complications

Citations (52)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4217344A (en)*1976-06-231980-08-12L'orealCompositions containing aqueous dispersions of lipid spheres
US4900747A (en)*1984-03-191990-02-13The Rockefeller UniversityMethod and agents for removing advanced glycosylation endproducts
US4911928A (en)*1987-03-131990-03-27Micro-Pak, Inc.Paucilamellar lipid vesicles
US4917951A (en)*1987-07-281990-04-17Micro-Pak, Inc.Lipid vesicles formed of surfactants and steroids
US5494791A (en)*1992-06-261996-02-27Exocell, Inc.Monoclonal antibodies against glycated low density lipoprotein
US5518720A (en)*1992-12-301996-05-21Exocell, Inc.Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin
US5601526A (en)*1991-12-201997-02-11Technomed Medical SystemsUltrasound therapy apparatus delivering ultrasound waves having thermal and cavitation effects
US5620479A (en)*1992-11-131997-04-15The Regents Of The University Of CaliforniaMethod and apparatus for thermal therapy of tumors
US5702704A (en)*1991-12-201997-12-30The Rockefeller UniversityAntibodies to in vivo advanced glycosylation endproducts
US5766590A (en)*1994-12-301998-06-16Alteon Inc.Therapeutic methods and pharmaceutical compositions
US5817771A (en)*1993-04-281998-10-06Worcester Foundation For Experimental BiologyCell-targeted lytic pore-forming agents
US5984882A (en)*1996-08-191999-11-16Angiosonics Inc.Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
US6067859A (en)*1999-03-042000-05-30The Board Of Regents, The University Of Texas SystemOptical stretcher
US6176842B1 (en)*1995-03-082001-01-23Ekos CorporationUltrasound assembly for use with light activated drugs
US6245318B1 (en)*1997-05-272001-06-12Mallinckrodt Inc.Selectively binding ultrasound contrast agents
US6309355B1 (en)*1998-12-222001-10-30The Regents Of The University Of MichiganMethod and assembly for performing ultrasound surgery using cavitation
US6380165B1 (en)*1997-09-192002-04-30The Picower Institute For Medical ResearchImmunological advanced glycation endproduct crosslink
US6387373B1 (en)*1993-01-152002-05-14Novavax, Inc.Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US20020193784A1 (en)*2001-03-072002-12-19Mchale Anthony PatrickUltrasound therapy for selective cell ablation
US20030170173A1 (en)*2000-05-232003-09-11Jo KlavenessContrast agents
US20030229283A1 (en)*2000-11-172003-12-11Craig Roger KingdonUltrasound therapy
US6670136B2 (en)*1998-10-062003-12-30The Trustees Of Columbia University In The City Of New YorkExtracellular novel RAGE binding protein (EN-RAGE) and uses thereof
US6676963B1 (en)*2000-10-272004-01-13Barnes-Jewish HospitalLigand-targeted emulsions carrying bioactive agents
US20040039416A1 (en)*2000-08-252004-02-26Gunnar MyhrApparatus for selective sell and virus destruction within a living organism
US20040141922A1 (en)*1996-10-282004-07-22Nycomed Imaging AsDiagnostic/therapeutic agents
US20040208826A1 (en)*1990-04-022004-10-21Bracco International B.V.Ultrasound contrast agents and methods of making and using them
US6818215B2 (en)*1991-12-162004-11-16James R. SmithAntibodies to senescent cell-derived inhibiters of DNA synthesis
US20050084538A1 (en)*2003-08-272005-04-21The Regents Of The University Of California, A California CorporationUltrasonic concentration of drug delivery capsules
US20050283098A1 (en)*1998-02-062005-12-22Conston Stanley RMethod for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
US20060078501A1 (en)*2004-01-202006-04-13Goertz David EHigh frequency ultrasound imaging using contrast agents
US7033574B1 (en)*1990-04-022006-04-25Bracco International B.V.Stable microbubbles suspensions injectable into living organisms
US20060188883A1 (en)*2003-03-082006-08-24Murray Graeme IMarkers for colorectal cancer
US7101838B2 (en)*1997-08-052006-09-05The Trustees Of Columbia University In The City Of New YorkMethod to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
US20070059247A1 (en)*2005-08-302007-03-15Lindner Jonathan RDeposit contrast agents and related methods thereof
US20070065415A1 (en)*2005-09-162007-03-22Kleinsek Donald ACompositions and methods for the augmentation and repair of defects in tissue
US20070083120A1 (en)*2005-09-222007-04-12Cain Charles APulsed cavitational ultrasound therapy
US20070129633A1 (en)*2005-11-232007-06-07Warren LeeAblation array having independently activated ablation elements
US20070128117A1 (en)*2003-02-042007-06-07Bracco International B.V.Ultrasound contrast agents and process for the preparation thereof
US7256273B2 (en)*2002-03-122007-08-14Elan Pharma International LimitedHumanized antibodies that recognize beta amyloid peptide
US20080051680A1 (en)*2004-10-112008-02-28Peter LuebckeApparatus for Treatment of Dermatological Conditions
US20080063603A1 (en)*1990-04-022008-03-13Bracco International B.V.Ultrasound contrast agents and methods of making and using them
US7367988B1 (en)*2000-02-022008-05-06The Catholic University Of AmericaUse of electromagnetic fields in cancer and other therapies
US20080139942A1 (en)*2005-03-032008-06-12Emmanuel GaudMedical Imaging System Based on a Targeted Contrast Agent
US20080160506A1 (en)*2000-10-092008-07-03Yung-Hsiang LiuImmunological analytical method and device for the determination of advanced glycosylation end products (AGEs)
US20090306552A1 (en)*2008-06-042009-12-10Japan Health Sciences FoundationUltrasonic medical apparatus
US20100028359A1 (en)*2008-05-092010-02-04Abbott Gmbh & Co. KgAntibodies to receptor of advanced glycation end products (rage) and uses thereof
US7751057B2 (en)*2008-01-182010-07-06The Board Of Trustees Of The University Of IllinoisMagnetomotive optical coherence tomography
US20100226932A1 (en)*2006-02-222010-09-09Novavax, Inc.Adjuvant and Vaccine Compositions
US20120130287A1 (en)*2010-11-222012-05-24Lewis GruberSelective removal of cells having accumulated agents
US20120183534A1 (en)*2008-05-232012-07-19Lewis GruberMethods, compositions and apparatuses for facilitating regeneration
US8343420B2 (en)*2009-09-172013-01-01Sanuwave, Inc.Methods and devices for cleaning and sterilization with shock waves
US20130243785A1 (en)*2010-09-272013-09-19Lewis GruberSelective removal of age-modified cells for treatment of atherosclerosis

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5811075A (en)1984-03-191998-09-22The Rockefeller UniversityMethod and agents for removing advanced glycosylation endproducts
AU600306B2 (en)*1986-09-121990-08-09Rockefeller University, TheMethods and agents for removing advanced glycosylation endproducts
US4965288A (en)*1988-02-251990-10-23Merrell Dow Pharmaceuticals Inc.Inhibitors of lysyl oxidase
US5530101A (en)*1988-12-281996-06-25Protein Design Labs, Inc.Humanized immunoglobulins
US6410598B1 (en)1994-02-032002-06-25Michael P. VitekCompositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5935927A (en)1994-02-031999-08-10The Picower Institute For Medical ResearchCompositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts
WO1996020958A1 (en)*1994-12-301996-07-11Alteon, Inc.Monoclonal antibodies specific for advanced glycosylation endproducts in biological samples
AU6907496A (en)1995-08-251997-03-19Case Western Reserve UniversityProcess for detecting pentosidine and for assessing the biological age of a biological sample
JP3579549B2 (en)1995-10-242004-10-20株式会社トクヤマ Use as a marker for diabetes or diabetic complications
US6090382A (en)1996-02-092000-07-18Basf AktiengesellschaftHuman antibodies that bind human TNFα
US5664570A (en)1996-02-201997-09-09SvcApparatus for applying high-intensity ultrasonic waves to a target volume within a human or animal body
US5908925A (en)*1996-06-271999-06-01Exocell, Inc.Genetically engineered immunoglobulins with specificity for glycated albumin
US7258857B2 (en)1996-11-222007-08-21The Trustees Of Columbia University In The City Of New YorkRage-related methods for treating inflammation
CN1270637A (en)1997-08-082000-10-18华盛顿大学Isolation of a novel senescence-factor gene, P23
JP4016304B2 (en)1998-02-262007-12-05日本油脂株式会社 Monoclonal antibody, hybrid cell, and method for producing monoclonal antibody
AU4556699A (en)*1998-06-091999-12-30Alteon Inc.Monoclonal antibodies specific for guanidino group-derived advanced glycosylation endproducts in biological samples
US6753150B2 (en)1998-10-052004-06-22The Trustees Of Columbia University In The City Of New YorkMethod for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
DK1159003T3 (en)1999-03-022011-02-07Centocor Inc Anti-tnfalfa antibodies for the treatment of steroid-resistant asthma
BRPI0012198B8 (en)1999-06-252021-05-25Genentech Inc humanized antibodies, composition and immunoconjugate
CA2382095A1 (en)*1999-08-132001-02-22The Trustees Of Columbia University In The City Of New YorkMethods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof
EP1219639A4 (en)1999-09-082009-03-25Toray IndustriesMaterials for extracorporeal circulation, adsorbents for diabetic complication factors, containers for eliminating diabetic complication factors and method of eliminating diabetic complication factors
EP1362223B1 (en)2001-01-032008-05-21Ultrashape Inc.Non-invasive ultrasonic body contouring
US7347855B2 (en)2001-10-292008-03-25Ultrashape Ltd.Non-invasive ultrasonic body contouring
ATE283481T1 (en)*2001-03-222004-12-15Hoffmann La Roche METHOD FOR FINDING REAGENTS AND SOLID PHASE COMPONENTS IN SPECIFIC BINDING ASSAY, FREE OF ADVANCED GLYCOSYLATION END PRODUCTS
WO2003008446A1 (en)2001-07-192003-01-30Mitsubishi Pharma CorporationPolypeptides relating to signal transfer of advanced glycation end product receptor
JP4012722B2 (en)2001-11-222007-11-21株式会社トランスジェニック Antibodies against carboxymethylated peptides
CA2492964C (en)2002-07-242012-07-17Qlt Inc.Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
AU2003265505A1 (en)2002-08-162004-03-03Imperial College Innovations LimitedCompositions and methods for treating rage-associated disorders
EP1597280B2 (en)2003-02-262016-08-24Institute for Research in BiomedicineMonoclonal antibody production by ebv transformation of b cells
JP2007500521A (en)*2003-07-312007-01-18ウッドウェルディング・アクチェンゲゼルシャフト Method and apparatus for promoting tissue regeneration on wound surface
AU2005214971A1 (en)*2004-02-172005-09-01Dynamis Therapeutics, Inc.Fructoseamine 3 kinase and the formation of collagen and elastin
WO2006012415A2 (en)2004-07-202006-02-02Critical Therapeutics, Inc.Rage protein derivatives
EP1781700B1 (en)2004-08-032014-03-19TransTech Pharma, LLCRage fusion proteins and methods of use
GT200600031A (en)2005-01-282006-08-29 ANTI-BETA ANTIBODY FORMULATION
JP2006249015A (en)*2005-03-112006-09-21Mochida Pharmaceut Co Ltd Cell aging inhibitor
KR20070094950A (en)2005-04-052007-09-27가부시끼가이샤 제이엠에스 Antibodies that specifically react to AAs derived from 3,4-DVE
US20070225242A1 (en)*2005-06-212007-09-27The Board Of Trustees Of The Leland Stanford Junior UniversityMethod and composition for treating and preventing tumor metastasis in vivo
US20070078290A1 (en)*2005-09-302007-04-05Esenaliev Rinat OUltrasound-based treatment methods for therapeutic treatment of skin and subcutaneous tissues
JP4779115B2 (en)2005-12-162011-09-28国立大学法人東北大学 Postoperative prognostic method for early lung cancer
WO2007100770A2 (en)2006-02-282007-09-07Elan Pharmaceuticals, Inc.Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2008144753A2 (en)2007-05-212008-11-27Alder Biopharmaceuticals, Inc.Antibodies to tnf alpha and use thereof
US20100249038A1 (en)2007-06-122010-09-30Board Of Regents, University Of Texas SystemAntagonists of the receptor for advanced glycation end-products (rage)
CA2690056C (en)2007-06-142017-08-29Galactica Pharmaceuticals, Inc.Rage fusion proteins
JP2007277263A (en)2007-07-132007-10-25Transgenic IncAntibody to carboxymethylated protein
US20120156134A1 (en)*2007-12-202012-06-21Shayne SquiresCompositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
DE102008009461A1 (en)2008-02-152009-08-20Beiersdorf AgReducing the wrinkle, comprises applying a cosmetic preparation on the skin to be treated and subsequently working up by means of an ultrasonic applicator
WO2010005531A2 (en)2008-06-302010-01-14The Johns Hopkins UniversityMethods for the detection of advanced glycation endproducts and markers for disease
WO2010095461A1 (en)2009-02-202010-08-26国立大学法人東京大学Novel monoclonal antibody, and use thereof
US20110070227A1 (en)2009-09-182011-03-24Anna-Marie Novotney-BarryTreatment of Autoimmune and Inflammatory Diseases
EP2493486A1 (en)2009-10-302012-09-05University Of Arkansas For Medical ScienceUse of autologous effector cells and antibodies for treatment of multiple myeloma
WO2011101039A1 (en)2010-02-222011-08-25Universite Pierre Et Marie Curie (Paris 6)Apparatus for the treatment of brain affections and method implementing thereof
KR101351181B1 (en)2010-05-112014-01-14가천대학교 산학협력단Method for inhibiting cell death induction by inhibiting synthesis or secretion of AGE-albumin in mononuclear phagocyte system
WO2012135616A1 (en)2011-03-312012-10-04Siwa CorporationVaccination against advanced glycation end-products
UA112434C2 (en)2011-05-272016-09-12Ґлаксо Ґруп Лімітед ANTIGENCY BINDING SPECIFICALLY Binds to ALL
US20130012816A1 (en)2011-07-102013-01-10Guided Therapy Systems, LlcMethods and systems for controlling acoustic energy deposition into a medium
US8954155B2 (en)2011-09-192015-02-10Biotalk Technologies IncApparatus and method for rejuvenating skin
US9422365B2 (en)2011-09-232016-08-23Julius-Maximilians-Universität WürzburgPeptide or arrangement of peptides forming a Staphylococcus aureus epitope binding site
US20140322216A1 (en)2011-11-082014-10-30The Trustees Of The University Of PennsylvaniaGlypican-3-specific antibody and uses thereof
KR101939401B1 (en)2011-11-102019-01-16가천대학교 산학협력단Composition for preventing or treating ischemic cardiac diseases comprising inhibiting agent for synthesis or secretion of AGE-albumin of mononuclear phagocyte as active ingredient
EA031069B1 (en)2012-02-172018-11-30Сиэтл Дженетикс, Инк.ANTIBODIES TO INTEGRIN αvβ6 AND USE OF SAME TO TREAT CANCER
TWI557112B (en)2012-03-052016-11-11百靈佳殷格翰國際股份有限公司Inhibitors of beta-secretase
US20130288980A1 (en)2012-04-022013-10-31Buck Institute For Research On AgingTargeting senescent and cancer cells for selective killing by interference with foxo4
US10379026B2 (en)2012-08-292019-08-13Inguran, LlcCell processing using magnetic particles
KR101520336B1 (en)2012-11-302015-05-14전남대학교산학협력단Compositions for prevention, improvement and treatment of Aging Phenotypes Comprising Recombinant Fusion Protein with Vibrio vulnificus Flagellin and Pathogenic Antigen
EP2742935A1 (en)2012-12-142014-06-18Tissue Med Biosciences Forschungs- und Entwicklungsgesellschaft mbHSERF2 for the treatment of atrophy and for increasing cell growth
AU2014224171B2 (en)2013-03-062018-02-01Protalix Ltd.Tnf alpha inhibitor polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
US20140257262A1 (en)2013-03-112014-09-11Alexandre CarpentierInterstitial ultrasonic disposable applicator and method for tissue thermal conformal volume ablation and monitoring the same
WO2014164680A1 (en)2013-03-122014-10-09Molecular Templates, Inc.Cd20-binding immunotoxins for inducing cellular internalization and methods using same
WO2015095227A2 (en)2013-12-162015-06-25Genentech, Inc.Peptidomimetic compounds and antibody-drug conjugates thereof
EP3087101B1 (en)2013-12-202024-06-05Novartis AGRegulatable chimeric antigen receptor
US10323083B2 (en)2014-01-152019-06-18The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesAgents that specifically bind matrilin-3 and their use
EP3096824A1 (en)2014-01-242016-11-30Cole Research&Design, Inc.Oral suction device
EP3669881B1 (en)2014-01-282022-03-30Buck Institute for Research on AgingCompositions for use in the treatment of senescence-assiocated eye disease and disorders
US20170216286A1 (en)2014-01-282017-08-03Mayo Foundation For Medical Education And ResearchKilling senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
DE102014107077B3 (en)2014-05-202015-08-13Ecs Engineered Control Systems Ag switching device
US10238742B2 (en)2014-06-252019-03-26Yale UniversityCell penetrating nucleolytic antibody based cancer therapy
MA40459A (en)2014-09-192016-03-24Siwa CorpAnti-age antibodies for treating inflammation and auto-immune disorders
US20170240632A1 (en)2014-10-162017-08-24The Broad Institute Inc.Compositions and methods for identifying and treating cachexia or pre-cachexia
US10358502B2 (en)2014-12-182019-07-23Siwa CorporationProduct and method for treating sarcopenia
US9993535B2 (en)2014-12-182018-06-12Siwa CorporationMethod and composition for treating sarcopenia
WO2017065837A1 (en)2015-10-132017-04-20Siwa CorporationAnti-age antibodies and methods of use thereof
US10889634B2 (en)2015-10-132021-01-12Siwa CorporationAnti-age antibodies and methods of use thereof
KR102503910B1 (en)2015-11-092023-02-27삼성전자주식회사Method and apparatus of standing assistance
PT3337829T (en)2016-02-192020-02-10Siwa Corp METHOD AND COMPOSITION FOR THE TREATMENT OF CANCER, KILLING METASTATIC CANCER CELLS AND PREVENTING CANCER METASTASES USING ANTIBODIES FOR FINAL PRODUCTS OF ADVANCED GLYCUS (PGA)
US10981021B2 (en)2016-03-112021-04-20CartheraMethod for transiently disrupting a region of the blood-brain barrier of a human
CN109311975A (en)2016-04-152019-02-05Siwa有限公司 Anti-AGE Antibodies for the Treatment of Neurodegenerative Disorders
US11213585B2 (en)2016-06-232022-01-04Siwa CorporationVaccines for use in treating various diseases and disorders
US10858449B1 (en)*2017-01-062020-12-08Siwa CorporationMethods and compositions for treating osteoarthritis
US10961321B1 (en)2017-01-062021-03-30Siwa CorporationMethods and compositions for treating pain associated with inflammation
US10995151B1 (en)2017-01-062021-05-04Siwa CorporationMethods and compositions for treating disease-related cachexia
US10925937B1 (en)2017-01-062021-02-23Siwa CorporationVaccines for use in treating juvenile disorders associated with inflammation
JP2020516648A (en)2017-04-132020-06-11シワ コーポレーション Humanized monoclonal advanced glycation end product antibody
KR20240006702A (en)2017-05-042024-01-15시와 코퍼레이션Diagnostic advanced glycation end-product antibodies
EP3826670A1 (en)2018-07-232021-06-02Siwa CorporationMethods and compositions for treating chronic effects of radiation and chemical exposure
KR20210045435A (en)2018-08-142021-04-26이멜 바이오테라퓨틱스, 인코포레이티드. Methods and compositions for treating mitochondrial diseases or disorders and heteroplasmy
WO2020041625A1 (en)2018-08-232020-02-27Siwa CorporationAnti carboxymethyl lysine antibodies and ultrasound for removing age-modified cells
EP4143238A1 (en)2020-05-012023-03-08Siwa CorporationMethods of treating infections
WO2021247397A2 (en)2020-06-042021-12-09Siwa CorporationMethods and compositions for enhancing the immune system

Patent Citations (57)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4217344A (en)*1976-06-231980-08-12L'orealCompositions containing aqueous dispersions of lipid spheres
US4900747A (en)*1984-03-191990-02-13The Rockefeller UniversityMethod and agents for removing advanced glycosylation endproducts
US4911928A (en)*1987-03-131990-03-27Micro-Pak, Inc.Paucilamellar lipid vesicles
US4917951A (en)*1987-07-281990-04-17Micro-Pak, Inc.Lipid vesicles formed of surfactants and steroids
US20040208826A1 (en)*1990-04-022004-10-21Bracco International B.V.Ultrasound contrast agents and methods of making and using them
US20080063603A1 (en)*1990-04-022008-03-13Bracco International B.V.Ultrasound contrast agents and methods of making and using them
US7033574B1 (en)*1990-04-022006-04-25Bracco International B.V.Stable microbubbles suspensions injectable into living organisms
US6818215B2 (en)*1991-12-162004-11-16James R. SmithAntibodies to senescent cell-derived inhibiters of DNA synthesis
US5702704A (en)*1991-12-201997-12-30The Rockefeller UniversityAntibodies to in vivo advanced glycosylation endproducts
US5601526A (en)*1991-12-201997-02-11Technomed Medical SystemsUltrasound therapy apparatus delivering ultrasound waves having thermal and cavitation effects
US5494791A (en)*1992-06-261996-02-27Exocell, Inc.Monoclonal antibodies against glycated low density lipoprotein
US5620479A (en)*1992-11-131997-04-15The Regents Of The University Of CaliforniaMethod and apparatus for thermal therapy of tumors
US5518720A (en)*1992-12-301996-05-21Exocell, Inc.Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin
US6387373B1 (en)*1993-01-152002-05-14Novavax, Inc.Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US5817771A (en)*1993-04-281998-10-06Worcester Foundation For Experimental BiologyCell-targeted lytic pore-forming agents
US5766590A (en)*1994-12-301998-06-16Alteon Inc.Therapeutic methods and pharmaceutical compositions
US20040229830A1 (en)*1995-03-052004-11-18Katsuro TachibanaDelivery of therapeutic compositions using ultrasound
US6176842B1 (en)*1995-03-082001-01-23Ekos CorporationUltrasound assembly for use with light activated drugs
US5984882A (en)*1996-08-191999-11-16Angiosonics Inc.Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
US20040141922A1 (en)*1996-10-282004-07-22Nycomed Imaging AsDiagnostic/therapeutic agents
US6245318B1 (en)*1997-05-272001-06-12Mallinckrodt Inc.Selectively binding ultrasound contrast agents
US7101838B2 (en)*1997-08-052006-09-05The Trustees Of Columbia University In The City Of New YorkMethod to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
US6380165B1 (en)*1997-09-192002-04-30The Picower Institute For Medical ResearchImmunological advanced glycation endproduct crosslink
US20050283098A1 (en)*1998-02-062005-12-22Conston Stanley RMethod for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
US6670136B2 (en)*1998-10-062003-12-30The Trustees Of Columbia University In The City Of New YorkExtracellular novel RAGE binding protein (EN-RAGE) and uses thereof
US6309355B1 (en)*1998-12-222001-10-30The Regents Of The University Of MichiganMethod and assembly for performing ultrasound surgery using cavitation
US6067859A (en)*1999-03-042000-05-30The Board Of Regents, The University Of Texas SystemOptical stretcher
US7367988B1 (en)*2000-02-022008-05-06The Catholic University Of AmericaUse of electromagnetic fields in cancer and other therapies
US20030170173A1 (en)*2000-05-232003-09-11Jo KlavenessContrast agents
US20040039416A1 (en)*2000-08-252004-02-26Gunnar MyhrApparatus for selective sell and virus destruction within a living organism
US20080160506A1 (en)*2000-10-092008-07-03Yung-Hsiang LiuImmunological analytical method and device for the determination of advanced glycosylation end products (AGEs)
US6676963B1 (en)*2000-10-272004-01-13Barnes-Jewish HospitalLigand-targeted emulsions carrying bioactive agents
US20030229283A1 (en)*2000-11-172003-12-11Craig Roger KingdonUltrasound therapy
US6821274B2 (en)*2001-03-072004-11-23Gendel Ltd.Ultrasound therapy for selective cell ablation
US20020193784A1 (en)*2001-03-072002-12-19Mchale Anthony PatrickUltrasound therapy for selective cell ablation
US7256273B2 (en)*2002-03-122007-08-14Elan Pharma International LimitedHumanized antibodies that recognize beta amyloid peptide
US20070128117A1 (en)*2003-02-042007-06-07Bracco International B.V.Ultrasound contrast agents and process for the preparation thereof
US20060188883A1 (en)*2003-03-082006-08-24Murray Graeme IMarkers for colorectal cancer
US20050084538A1 (en)*2003-08-272005-04-21The Regents Of The University Of California, A California CorporationUltrasonic concentration of drug delivery capsules
US7358226B2 (en)*2003-08-272008-04-15The Regents Of The University Of CaliforniaUltrasonic concentration of drug delivery capsules
US20060078501A1 (en)*2004-01-202006-04-13Goertz David EHigh frequency ultrasound imaging using contrast agents
US20080051680A1 (en)*2004-10-112008-02-28Peter LuebckeApparatus for Treatment of Dermatological Conditions
US20080139942A1 (en)*2005-03-032008-06-12Emmanuel GaudMedical Imaging System Based on a Targeted Contrast Agent
US20070059247A1 (en)*2005-08-302007-03-15Lindner Jonathan RDeposit contrast agents and related methods thereof
US20070065415A1 (en)*2005-09-162007-03-22Kleinsek Donald ACompositions and methods for the augmentation and repair of defects in tissue
US20070083120A1 (en)*2005-09-222007-04-12Cain Charles APulsed cavitational ultrasound therapy
US20090076390A1 (en)*2005-11-232009-03-19Warren LeeIntegrated ultrasound imaging and ablation probe
US20070129633A1 (en)*2005-11-232007-06-07Warren LeeAblation array having independently activated ablation elements
US20100226932A1 (en)*2006-02-222010-09-09Novavax, Inc.Adjuvant and Vaccine Compositions
US7751057B2 (en)*2008-01-182010-07-06The Board Of Trustees Of The University Of IllinoisMagnetomotive optical coherence tomography
US20100028359A1 (en)*2008-05-092010-02-04Abbott Gmbh & Co. KgAntibodies to receptor of advanced glycation end products (rage) and uses thereof
US20120183534A1 (en)*2008-05-232012-07-19Lewis GruberMethods, compositions and apparatuses for facilitating regeneration
US20090306552A1 (en)*2008-06-042009-12-10Japan Health Sciences FoundationUltrasonic medical apparatus
US8343420B2 (en)*2009-09-172013-01-01Sanuwave, Inc.Methods and devices for cleaning and sterilization with shock waves
US20130243785A1 (en)*2010-09-272013-09-19Lewis GruberSelective removal of age-modified cells for treatment of atherosclerosis
US20120130287A1 (en)*2010-11-222012-05-24Lewis GruberSelective removal of cells having accumulated agents
US8721571B2 (en)*2010-11-222014-05-13Siwa CorporationSelective removal of cells having accumulated agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALSUntangled No. 23: The Rife Machine and retroviruses, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014; 15: 157-159*
Campisi et al., Cellular senescence: when bad things happen to good cells, Nature Reviews: Molecular Cell Biology, Vol. 8, p. 729-749, September 2008*
Lv, et al., Low-intensity Ultrasound Combined with 5-aminolevulinic Acid Administration in the Treatment of Human Tongue Squamous Carcinoma, Cell Physiol. Biochem. 2012; 30:321-333*
Peppa et al., Glucose, Advanced Glycation End Products, and Diabetes Complications: What Is New and What Works, Clinical Diabetes October 2003 vol. 21 no. 4 186-187*
Roylance, "MECHANICAL PROPERTIES OF MATERIALS" (2008), available at http://web.mit.edu/course/3/3.225/book.pdf*

Cited By (25)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US9161810B2 (en)2008-05-232015-10-20Siwa CorporationMethods, compositions and apparatuses for facilitating regeneration
US11261241B2 (en)2008-05-232022-03-01Siwa CorporationMethods, compositions and apparatuses for facilitating regeneration
US9649376B2 (en)2010-09-272017-05-16Siwa CorporationSelective removal of age-modified cells for treatment of atherosclerosis
US10226531B2 (en)2010-09-272019-03-12Siwa CorporationSelective removal of age-modified cells for treatment of atherosclerosis
US8721571B2 (en)2010-11-222014-05-13Siwa CorporationSelective removal of cells having accumulated agents
US9320919B2 (en)2010-11-222016-04-26Siwa CorporationSelective removal of cells having accumulated agents
US10960234B2 (en)*2010-11-222021-03-30Siwa CorporationSelective removal of cells having accumulated agents
US20160101299A1 (en)*2010-11-222016-04-14Siwa CorporationSelective removal of cells having accumulated agents
US10584180B2 (en)2014-09-192020-03-10Siwa CorporationAnti-AGE antibodies for treating inflammation and auto-immune disorders
US12134660B2 (en)2014-09-192024-11-05Siwa CorporationAnti-age antibodies for treating inflammation and auto-immune disorders
US9993535B2 (en)2014-12-182018-06-12Siwa CorporationMethod and composition for treating sarcopenia
US10358502B2 (en)2014-12-182019-07-23Siwa CorporationProduct and method for treating sarcopenia
US11873345B2 (en)2014-12-182024-01-16Siwa CorporationProduct and method for treating sarcopenia
US11872269B2 (en)2014-12-182024-01-16Siwa CorporationMethod and composition for treating sarcopenia
US11833202B2 (en)2016-02-192023-12-05Siwa CorporationMethod and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE)
US11958900B2 (en)2016-04-152024-04-16Siwa CorporationAnti-age antibodies for treating neurodegenerative disorders
US11213585B2 (en)2016-06-232022-01-04Siwa CorporationVaccines for use in treating various diseases and disorders
US10961321B1 (en)2017-01-062021-03-30Siwa CorporationMethods and compositions for treating pain associated with inflammation
US10995151B1 (en)2017-01-062021-05-04Siwa CorporationMethods and compositions for treating disease-related cachexia
US10925937B1 (en)2017-01-062021-02-23Siwa CorporationVaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en)2017-01-062020-12-08Siwa CorporationMethods and compositions for treating osteoarthritis
US11542324B2 (en)2017-04-132023-01-03Siwa CorporationHumanized monoclonal advanced glycation end-product antibody
US10919957B2 (en)2017-04-132021-02-16Siwa CorporationHumanized monoclonal advanced glycation end-product antibody
US12226465B2 (en)2017-04-132025-02-18Siwa CorporationHumanized monoclonal advanced glycation end-product antibody
US11518801B1 (en)2017-12-222022-12-06Siwa CorporationMethods and compositions for treating diabetes and diabetic complications

Also Published As

Publication numberPublication date
RU2015114990A (en)2015-11-27
KR101537460B1 (en)2015-07-16
KR20130132658A (en)2013-12-04
BRPI0913047A2 (en)2013-03-05
JP2022089873A (en)2022-06-16
CN104987416A (en)2015-10-21
MX2010012473A (en)2011-02-23
HK1150628A1 (en)2012-01-06
CN102037119A (en)2011-04-27
JP6359051B2 (en)2018-07-18
US20160152697A1 (en)2016-06-02
ES2616728T3 (en)2017-06-14
EP2789684B1 (en)2016-12-21
JP2017125073A (en)2017-07-20
JP2011521009A (en)2011-07-21
HUE031902T2 (en)2017-08-28
HK1200485A1 (en)2015-08-07
CA2724886C (en)2017-11-14
ES2499395T3 (en)2014-09-29
PL2789684T3 (en)2017-06-30
IL209513A (en)2015-08-31
JP6637465B2 (en)2020-01-29
WO2009143411A2 (en)2009-11-26
EP3170888A1 (en)2017-05-24
KR20120127543A (en)2012-11-21
EP2789684A1 (en)2014-10-15
RU2553225C2 (en)2015-06-10
CN102037119B (en)2015-06-24
AU2009248945A1 (en)2009-11-26
EP2294178B1 (en)2014-07-16
US20120183534A1 (en)2012-07-19
JP2020050666A (en)2020-04-02
MX342994B (en)2016-10-21
KR20110000585A (en)2011-01-03
IL240242A0 (en)2015-09-24
WO2009143411A3 (en)2010-01-14
US11261241B2 (en)2022-03-01
JP2016152815A (en)2016-08-25
ZA201008209B (en)2012-04-25
US9161810B2 (en)2015-10-20
EP2294178A4 (en)2011-12-07
CA2724886A1 (en)2009-11-26
DK2789684T3 (en)2017-02-20
KR20150041158A (en)2015-04-15
JP2015131846A (en)2015-07-23
PT2789684T (en)2017-02-14
IL209513A0 (en)2011-01-31
US20180111982A2 (en)2018-04-26
US20180044411A1 (en)2018-02-15
EP2294178A2 (en)2011-03-16
RU2010152693A (en)2012-06-27
IL248652A0 (en)2016-12-29
AU2009248945B2 (en)2014-02-13
KR101592156B1 (en)2016-02-04
RU2640249C2 (en)2017-12-27

Similar Documents

PublicationPublication DateTitle
US11261241B2 (en)Methods, compositions and apparatuses for facilitating regeneration
AU2014202548A1 (en)Methods, compositions and apparatuses for facilitating regeneration
HK1236562A1 (en)Methods and compositions for facilitating regeneration
HK1236562A (en)Methods and compositions for facilitating regeneration
HK1150628B (en)Methods for facilitating regeneration
HK1200485B (en)Methods and compositions for facilitating regeneration
PakhomovSurgical treatment of post-traumatic defects of the soft tissues of the head with necrosis of the calvarial bones.

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:SIWA CORPORATION, ILLINOIS

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GRUBER, LEWIS;REEL/FRAME:026025/0313

Effective date:20110110

STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION


[8]ページ先頭

©2009-2025 Movatter.jp